MX2021002474A - Administracion prolongada de lasmiditan por la noche para la prevencion de la migra?a. - Google Patents

Administracion prolongada de lasmiditan por la noche para la prevencion de la migra?a.

Info

Publication number
MX2021002474A
MX2021002474A MX2021002474A MX2021002474A MX2021002474A MX 2021002474 A MX2021002474 A MX 2021002474A MX 2021002474 A MX2021002474 A MX 2021002474A MX 2021002474 A MX2021002474 A MX 2021002474A MX 2021002474 A MX2021002474 A MX 2021002474A
Authority
MX
Mexico
Prior art keywords
lasmiditan
migraine
prevention
chronic nightly
migraine prevention
Prior art date
Application number
MX2021002474A
Other languages
English (en)
Inventor
Kirk Willis Johnson
Robert Russell Conley
Gudarz Davar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021002474A publication Critical patent/MX2021002474A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere al uso prolongado de lasmiditan por la noche para la prevención de la migraña, particularmente la migraña resistente al tratamiento que se define en el presente documento como migraña refractaria a dos o más esquemas de prevención o tratamiento previos de monoterapia y/o terapia doble.
MX2021002474A 2018-09-04 2019-09-03 Administracion prolongada de lasmiditan por la noche para la prevencion de la migra?a. MX2021002474A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (1)

Publication Number Publication Date
MX2021002474A true MX2021002474A (es) 2021-08-24

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002474A MX2021002474A (es) 2018-09-04 2019-09-03 Administracion prolongada de lasmiditan por la noche para la prevencion de la migra?a.

Country Status (35)

Country Link
US (1) US20210338655A1 (es)
EP (2) EP3846810B1 (es)
JP (2) JP7321256B2 (es)
KR (1) KR102649644B1 (es)
CN (1) CN112638383A (es)
AU (2) AU2019336667B2 (es)
BR (1) BR112021002945A2 (es)
CA (1) CA3111205A1 (es)
CL (1) CL2021000529A1 (es)
CO (1) CO2021002766A2 (es)
CR (1) CR20210126A (es)
DK (1) DK3846810T3 (es)
DO (1) DOP2021000039A (es)
EA (1) EA202190440A1 (es)
EC (1) ECSP21015491A (es)
ES (1) ES2967665T3 (es)
FI (1) FI3846810T3 (es)
HR (1) HRP20231587T1 (es)
HU (1) HUE064519T2 (es)
IL (1) IL281208A (es)
JO (1) JOP20210033A1 (es)
LT (1) LT3846810T (es)
MA (1) MA53551B1 (es)
MD (1) MD3846810T2 (es)
MX (1) MX2021002474A (es)
NZ (1) NZ774400A (es)
PE (1) PE20211599A1 (es)
PH (1) PH12021550448A1 (es)
PL (1) PL3846810T3 (es)
PT (1) PT3846810T (es)
RS (1) RS64857B1 (es)
SG (1) SG11202101530PA (es)
SI (1) SI3846810T1 (es)
TW (1) TWI826514B (es)
WO (1) WO2020051137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
MX2023001071A (es) * 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
PT2413933T (pt) * 2009-04-02 2017-12-12 Colucid Pharmaceuticals Inc Composição de 2,4,6-trifluoro-n-[6-(1-metil-piperidin-4-ilcarbonil)-piridin-2-il]-benzamida
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists

Also Published As

Publication number Publication date
FI3846810T3 (fi) 2023-12-15
CA3111205A1 (en) 2020-03-12
TW202033197A (zh) 2020-09-16
DK3846810T3 (da) 2023-12-04
EP3846810A1 (en) 2021-07-14
PL3846810T3 (pl) 2024-03-18
AU2019336667A1 (en) 2021-03-11
HRP20231587T1 (hr) 2024-03-15
PT3846810T (pt) 2023-12-14
ECSP21015491A (es) 2021-04-29
JOP20210033A1 (ar) 2021-02-25
JP2021535913A (ja) 2021-12-23
KR102649644B1 (ko) 2024-03-21
CO2021002766A2 (es) 2021-03-19
MD3846810T2 (ro) 2024-04-30
EA202190440A1 (ru) 2021-06-24
AU2019336667B2 (en) 2022-09-29
BR112021002945A2 (pt) 2021-05-11
NZ774400A (en) 2024-03-22
ES2967665T3 (es) 2024-05-03
WO2020051137A1 (en) 2020-03-12
EP4279132A2 (en) 2023-11-22
JP7321256B2 (ja) 2023-08-04
EP4279132A3 (en) 2024-03-06
SG11202101530PA (en) 2021-03-30
IL281208A (en) 2021-04-29
RS64857B1 (sr) 2023-12-29
JP2023156344A (ja) 2023-10-24
TWI826514B (zh) 2023-12-21
US20210338655A1 (en) 2021-11-04
EP3846810B1 (en) 2023-10-18
CL2021000529A1 (es) 2021-08-13
DOP2021000039A (es) 2021-03-31
CR20210126A (es) 2021-04-22
PH12021550448A1 (en) 2021-09-27
HUE064519T2 (hu) 2024-03-28
PE20211599A1 (es) 2021-08-18
KR20210039419A (ko) 2021-04-09
MA53551A (fr) 2022-01-12
CN112638383A (zh) 2021-04-09
LT3846810T (lt) 2024-01-10
SI3846810T1 (sl) 2023-12-29
MA53551B1 (fr) 2023-11-30
AU2022291568A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
PH12017502103A1 (en) Methods and kits for treating depression
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
MX2023008760A (es) Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
PH12015502028A1 (en) Ido inhibitors
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2019014784A (es) Tratamiento para la migra?a.
MX2022005347A (es) Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.